期刊论文详细信息
Biomarker Research
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
Alexandra Schrader1  Linus Wahnschaffe1  Marco Herling1  Sebastian Oberbeck1  Dennis Jungherz1  Kostantino Stamatakis2  Manuel Fresno2  Edgar Faber3  Emma I. Andersson4  Satu Mustjoki5  Javier Loscertales6  Fernando Terrón7  María Luisa Toribio8  Patricia Fuentes8  Arantzazu Alfranca9  Yaiza Pérez-García9  Ana Marcos-Jimenez9  Ana Urzainqui9  Tamara Mateu-Albero9  Anna Kreutzman9  Marina Espartero-Santos9  Blanca Andrea Sánchez-López9  Raquel Juárez-Sánchez1,10  Carlos Cuesta-Mateos1,10  Cecilia Muñoz-Calleja1,11  Lorena Vega-Piris1,12 
[1] Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf (ABCD), Cologne Cluster of Excellence in Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC), The University of Cologne, Cologne, Germany;Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain;Department of Hemato-Oncology, Faculty Hospital Olomouc, Faculty of Medicine and Dentistry Palacky University, Olomouc, Czech Republic;Department of Hematology, Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;Department of Hematology, Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;Translational Immunology Research Program and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland;Hematology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain;IMMED S.L., Immunological and Medicinal Products, Madrid, Spain;Immune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain;Immunology Department, Hospital Universitario de La Princesa, IIS-IP, C/ Diego de León 62, 28006, Madrid, Spain;Immunology Department, Hospital Universitario de La Princesa, IIS-IP, C/ Diego de León 62, 28006, Madrid, Spain;IMMED S.L., Immunological and Medicinal Products, Madrid, Spain;Immunology Department, Hospital Universitario de La Princesa, IIS-IP, C/ Diego de León 62, 28006, Madrid, Spain;Universidad Autónoma de Madrid, Madrid, Spain;Methodology Unit, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain;
关键词: CCR7;    T-PLL;    mAb;    T-cell lymphomas;    Immunotherapy;   
DOI  :  10.1186/s40364-020-00234-z
来源: Springer
PDF
【 摘 要 】

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 is a molecule expressed in a wide range of malignancies and relevant in many tumor processes, the present study addressed the biologic role of this receptor in T-PLL. Furthermore, we elucidated the mechanisms of action mediated by an anti-CCR7 monoclonal antibody (mAb) and evaluated whether its anti-tumor activity would warrant development towards clinical applications in T-PLL. Our results demonstrate that CCR7 is a prognostic biomarker for overall survival in T-PLL patients and a functional receptor involved in the migration, invasion, and survival of leukemic cells. Targeting CCR7 with a mAb inhibited ligand-mediated signaling pathways and induced tumor cell killing in primary samples. In addition, directing antibodies against CCR7 was highly effective in T-cell leukemia xenograft models. Together, these findings make CCR7 an attractive molecule for novel mAb-based therapeutic applications in T-PLL, a disease where recent drug screen efforts and studies addressing new compounds have focused on chemotherapy or small molecules.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202104284501253ZK.pdf 2658KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:2次